VIGL News and Press, Vigil Neuroscience Inc. From 01/03/24

- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 - - Extends projected cash runway into second half of 2025 - - Company to present at J.P. Morgan Healt...

2023-11-22 17:09:08 ET Gainers: Aurora Innovation ( AUR ) +2% . Innodata  ( INOD ) +2% . The Vita Coco Company ( COCO ) +2% . Immunovant ( IMVT ) +2% . The RealReal ( REAL ) +2% . Losers: BioCryst Pharmaceuticals ( ...

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph....

2023-11-20 19:34:03 ET Summary Positive interim results reported from phase 2 IGNITE study using iluzanebart for ALSP treatment from 6 patients. Additional results from phase 2 IGNITE study usung iluzanebart for the treatment of patients with ALSP from both 20 mg and 40 mg doses e...

2023-11-17 12:41:25 ET Gainers: Altamira Therapeutics Ltd ( CYTO ) +255% . Safe and Green Development Corp ( SGD ) +89% . Fortress Biotech ( FBIO ) +50% . Mural Oncology Plc ( MURA ) +40% . Syntec Optics Holdings ( OPTX ) +35% . ...

2023-11-17 10:00:08 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Curis, Emergen...

2023-11-16 17:42:36 ET More on Vigil Neuroscience Vigil Neuroscience: Interesting Early Data, Wait For Phase 2 Vigil Neuroscience GAAP EPS of -$0.53 beats by $0.03 Vigil Neuro rises as dosing starts in Phase 1 trial for Alzheimer’s drug Seeking Alpha&#...

- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent with Phase 1 data; Directionally supportive changes in individual patients at 6 months on ...

Vigil Neuroscience Inc. (VIGL) is expected to report $-0.57 for Q3 2023

2023-11-07 08:41:43 ET More on Vigil Neuroscience Vigil Neuroscience: Interesting Early Data, Wait For Phase 2 Vigil Neuro rises as dosing starts in Phase 1 trial for Alzheimer’s drug Vigil Neuroscience study for Alzheimer's drug to proceed with FDA restrictio...